You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Postexposure prophylaxis with oseltamivir reduced influenza transmission in households

https://doi.org/10.1136/ebm.9.5.142

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004;189:440–9.
    OpenUrlAbstract/FREE Full Text

    
 
 Q In household contacts (HHCs) (after index influenza [flu] patients received oseltamivir), is postexposure prophylaxis (PEP) more effective than oseltamivir treatment at the time of illness (expectant treatment) for preventing flu transmission?

    Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Infectious diseases ★★★★★★☆

    METHODS

    Embedded ImageDesign:

    cluster (household level) randomised controlled trial.

    Embedded ImageAllocation:

    {concealed}†.*

    Embedded ImageBlinding:

    unblinded.*

    Embedded ImageFollow up period:

    30 days.

    Embedded ImageSetting:

    households in Europe and North America.

    Embedded ImageParticipants:

    812 HHCs (age range 1–83 y, 55% girls/women) of index patients with a flu like illness during a community flu outbreak. Eligible households had 3–8 members, including ⩾1 index patient and ⩾2 eligible contacts ⩾1 year of age. Exclusion criteria included pregnancy, breastfeeding, and cancer.

    Embedded ImageIntervention:

    households were allocated to PEP (n = 138 households with 410 HHCs) or expectant treatment (n = 139 …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • ↵† Information provided by author.

    • For correspondence: Professor F G Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA. fghvirginia.edu

    • Source of funding: Hoffman-La Roche, Inc.